Research Analysts’ Weekly Ratings Changes for Sionna Therapeutics (SION)
by Amy Steele · The Cerbat GemSionna Therapeutics (NASDAQ: SION) has recently received a number of price target changes and ratings updates:
- 5/13/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.
- 5/8/2026 – Sionna Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 5/5/2026 – Sionna Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $53.00 price target on the stock.
- 5/4/2026 – Sionna Therapeutics was upgraded by Wedbush to “strong-buy”.
- 4/28/2026 – Sionna Therapeutics had its price target raised by JonesTrading from $52.00 to $63.00. They now have a “buy” rating on the stock.
- 4/27/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.
Insider Activity
In other news, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,717,760 shares of company stock valued at $77,562,902. 3.90% of the stock is currently owned by corporate insiders.
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.